Nucleotide and predicted amino acid sequences of cloned human and mouse preprocathepsin B cDNAs by Chan, Shu Jin et al.
Proc. Natl. Acad. Sci. USA
Vol. 83, pp. 7721-7725, October 1986
Biochemistry
Nucleotide and predicted amino acid sequences of cloned human
and mouse preprocathepsin B cDNAs
(cysteine proteinases/cathepsin B gene/precursor processing/lysosomal sorting)
SHU JIN CHAN, BLANCA SAN SEGUNDO*, MARY BETH MCCORMICK, AND DONALD F. STEINER
The Howard Hughes Medical Institute, Department of Biochemistry and Molecular Biology, The University of Chicago, 920 East 58th Street, Chicago, IL
60637
Contributed by Donald F. Steiner, July 14, 1986
ABSTRACT Cathepsin B is a lysosomal thiol proteinase
that may have additional extralysosomal functions. To further
our investigations on the structure, mode of biosynthesis, and
intracellular sorting of this enzyme, we have determined the
complete coding sequences for human and mouse preproca-
thepsin B by using cDNA clones isolated from human hepatoma
and kidney phage libraries. The nucleotide sequences predict
that the primary structure of preprocathepsin B contains 339
amino acids organized as follows: a 17-residue NH2-terminal
prepeptide sequence followed by a 62-residue propeptide
region, 254 residues in mature (single chain) cathepsin B, and
a 6-residue extension at the COOH terminus. A comparison of
procathepsin B sequences from three species (human, mouse,
and rat) reveals that the homology between the propeptides is
relatively conserved with a minimum of 68% sequence identity.
In particular, two conserved sequences in the propeptide that
may be functionally significant include a potential glycosylation
site and the presence of a single cysteine at position 59.
Comparative analysis of the three sequences also suggests that
processing of procathepsin B is a multistep process, during
which enzymatically active intermediate forms may be gener-
ated. The availability of the cDNA clones will facilitate the
identification of possible active or inactive intermediate
processive forms as well as studies on the transcriptional
regulation of the cathepsin B gene.
Cathepsin B is a member of a superfamily of structurally
similar tissue proteinases having a catalytic unit of -25 kDa
that contains an active center made up of side chains derived
from a cysteine residue located in its NH2-terminal region and
a more COOH-terminally located histidine residue (1). These
thiol proteinases are structurally and functionally closely
related to papain as well as to actinidin, both plant enzymes
(2). Cathepsin B also shows significant amino acid sequence
homology to the proteolytic domain of the cytosolic calcium-
dependent proteases (3), indicating that further evolutionary
diversification has occurred within this proteolytic superfam-
ily. Mature cathepsin B and the related thiol cathepsins H and
L as well as a number of other exo- or endoproteinases have
been localized to the lysosomes in various cells, indicating
that these proteinases are involved in protein turnover (4).
Recent biosynthetic studies in our laboratory have indi-
cated that cathepsin B is derived in biosynthesis from a larger
precursor form, or procathepsin B, which in its glycosylated
state has a molecular size of -40 kDa (5). In isolated islets of
Langerhans, this precursor form is either secreted into the
medium or is slowly converted to material similar in size and
immunological properties to mature cathepsin B and local-
ized in lysosomal and secretion granule fractions; e.g.,
Docherty et al. (6) have identified both 31-kDa and 38-kDa
cathepsin B-like proteins in purified secretion granules from
a rat insulinoma and in normal rat islet granule fractions (7).
A functional role for (pro)cathepsin B in the secretory
vesicles has not been established, but it may be involved in
prohormone conversion or, alternatively, in peptide hormone
degradation (8). In addition, the secretion of higher molecular
weight latent or active forms of cathepsin B, or closely
related enzymes, has also been observed from a wide variety
of tumors in vivo and in vitro (9-11), and this has led to
speculations that overproduction of the enzyme may play
some role in the transformed phenotype of some malignant
tumors (12, 13).
To investigate these manifold questions surrounding the
biosynthesis, intracellular targeting, secretion, and possible
extralysosomal functions of cathepsin B, we have cloned
cDNAs encoding the precursor from several species. In this
paper, we report the structures of cDNAs encoding nearly
full-length mRNAs for both the human and mouse precur-
sors. We show that these contain a prepeptide, or signal
peptide, region for segregation of the precursor into the
lumen of the rough endoplasmic reticulum as well as a lengthy
prosegment on the NH2-terminal side of the catalytic domain,
which exhibits several interesting features.
MATERIALS AND METHODS
Materials. Restriction endonucleases, T4 polynucleotide
kinase, T4 DNA ligase, and Escherichia coli DNA polymer-
ase (Klenow) were obtained from New England Biolabs or
Boehringer Mannheim. Plasmid vector pGEM2 DNA was
purchased from Promega Biotec (Madison, WI). Nitrocellu-
lose filter circles were obtained from Schleicher & Schuell.
Radioactive nucleotides were purchased from Amersham.
Isolation of cDNA Clones. A human hepatoma cDNA
library, cloned into Xgtll, was obtained from J. DeWet (San
Diego, CA) and has been described (14). A Xgtl0 human
kidney cDNA library was obtained from G. Bell (Chiron,
Emeryville, CA). The libraries were grown in 150-mm media
plates at a density of 40,000 plaques per plate in E. coli strains
Y1088 or BNN102 (15). Duplicate nitrocellulose filter lifts
were prepared, hybridized with a nick-translated 950-base-
pair (bp) EcoRI rat cathepsin B cDNA fragment isolated from
XrcB3 (16), and washed under reduced-stringency conditions
(17). After autoradiography, selected positive clones were
plaque-purified and phage DNA was isolated, digested with
EcoRI to release the cloned cDNA fragment, and subcloned
into plasmid vector pGEM2 for further analysis.
Sequence Analysis. DNA sequences were determined by
the chemical degradation procedure of Maxam and Gilbert
(18) and the dideoxynucleotide chain-termination method of
Sanger (19) after subcloning into M13. Specific primers for
dideoxynucleotide sequencing were synthesized on an Ap-
Abbreviation: bp, base pair(s).
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FIG. 1. Restriction map and sequencing strategy for mouse preprocathepsin B cDNA. The map was constructed from overlapping clones
XmCB14, XmCB54, and XmCB58 as shown. Arrows indicate 5' to 3' direction and length of each sequenced fragment. UT, untranslated.
plied Biosystems (Foster City, CA) model 380A DNA syn-
thesizer and purified by polyacrylamide gel electrophoresis in
7 M urea (20).
RESULTS
To isolate human preprocathepsin B cDNA clones, we
screened a Xgtll human hepatoma cDNA library obtained
from J. DeWet, using cloned rat cathepsin B cDNA as the
hybridization probe and reduced-stringency conditions as
described. Approximately 60 positive signals were observed
from 900,000 plaques in the initial screening. Although the
strength of the autoradiographic signals was variable, the
positive plaques on duplicate filters could be consistently
separated into two classes: strongly reactive clones and more
weakly reactive ones. We plaque-purified three repre-
sentative clones from each class, extracted phage DNA,
digested with EcoRI, and subcloned the cDNA inserts into
the plasmid form for further analysis.
Restriction endonuclease mapping revealed that the cDNA
inserts from the strongly reactive clones were overlapping,
and thus originated from a single mRNA species. In addition,
DNA sequence analysis revealed that the clones were 93%
homologous to the rat preprocathepsin B cDNA sequence
within the coding region, and these clones, designated
XmCB14, XmCB54, and XmCB58 were identified as encoding
mouse preprocathepsin B mRNA (Fig. 1).
Similar restriction mapping of the three weakly reactive
clones showed that the cDNA inserts from these also over-
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lapped and were derived from a second distinct mRNA
species. DNA sequence analysis revealed an extended open
reading frame in which the deduced amino acid sequence was
in agreement with the published sequence for mature human
cathepsin B (21). Based on these results, clones XhCB3,
XhCB4, and XhCB8 were identified as encoding human
preprocathepsin B mRNA (Fig. 2).
Because we are interested in comparing the expression of
tumor form(s) of preprocathepsin B with preprocathepsin B
in normal human tissues, we also screened XgtlO normal
human kidney cDNA library with rat cathepsin B cDNA. One
clone (XhCB79) containing a 2000-bp insert was isolated,
restriction-mapped, and sequenced by using the strategy
illustrated in Fig. 2.
The nucleotide sequence and deduced amino acid se-
quence for human preprocathepsin B cDNA is shown in Fig.
3. In comparing the kidney and hepatoma clones, no se-
quence differences were detected in the 5' overlapping or 3'
untranslated regions, and a single nucleotide change was
found in the coding region. The change, a dC to dG transition
at position 120, however, resulted in a silent substitution in
the codon for arginine and may reflect an allelic variation or
a cloning artifact. In a Southern blot ofhuman genomic DNA
digested with several restriction enzymes, hybridization with
labeled phCB79 revealed a simple fragmentation pattern
consistent with the presence of a single copy gene (data not
shown). These results also are essentially in agreement with
the recently reported partial sequence of a human cathepsin
B cDNA clone (30). We conclude that both human tumor and
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FIG. 2. Restriction map and sequencing strategy for human preprocathepsin B cDNA. The map was constructed from hepatomacDNA clones
XhCB3, XhCB4, and XhCB8, and from human kidney cDNA clone XhCB79, spanning the regions indicated. Arrows indicate 5' to 3' direction
and length of each sequenced fragment. UT, untranslated.
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Human AATTCCGCGGCAACCGCTCCGGCAACGCCAACCGCTCCGCTGCGCGCAGGCTGGGCTGCAGGCTCTCGGCTGCAG -120
Human CCGGTGGGATGGGCAGCCCGACTACACAAGAGGTTGTCACCGCTCATGGACAGTTGTCAC-1
House CTGCGCTCGGTGAGTGCAGGATCCAGCATCCAGG
Rat T
1 20
Net Trp Gsi Lem Trp Ala Ser Leu Cys Cys Lem Lem Val Leu Ala Asn AlatArg Ser Arg Pro 5cr Phe His Pro Val Ser Asp Glu 1em
Human ATG TGG CAG CTC TGG GCC TCC CTC TGC TGC CTG CTG GTG TTG GCC AAT GCC CGG AGC AGG CCC TCT TTC CAT CCC GTG TCG GAT GAG CTG 90
Mouse ATG TGG TGG TCC TTG ATC CIT CTT TCT TGC CTG CTG GCA CTG ACC AGT GCC CAT GAC AAG CCT TCC TTC CAC CCG CTG TCG GAT GAC CTG
Rat C C T A C A
Net Trp Trp Ser Lem Ilie Lem Leu Ser Cys Leu 1em Ala Leu Thr Ser Ala His Asp Lys Pro Ser Phe His Pro 1em 5cr Asp Asp Leu
Pro Met
40 60
Val Asm Tyr Val Asm Lys Arg Asn Thr Thr Trp Gin Ala Sly His Asn Phe Tyr Asn Val Asp Met 5cr Tyr Leu Lys Arg 1em Cys Gly
Human GTC AAC TAT GTC AAC AAA CGG AAT ACC ACG TGG CAG GCC GGG CAC AAC TTC TAC AAC GIG GAC ATG AGC TAC TTG AAG AGG CTA TGT GGT 180
Mouse ATT AAC TAT ATC AAC AAA CAG AAT ACA ACA TGG CAG GCT GGA CGC AAC TTC TAC AAT GIT GAC ATA AGC TAT CTG AAG AAG CTG TGT GGC
Rat C A
Ilie Aso Tyr Ilie Aso Lys Gin Aso Thr Thr Trp Gin Ala Sly Arg Asn Phe Tyr Asn Val Asp Ilie 5cr Tyr 1em Lys Lys 1ev Cys Sly
Pro
80
Thr Phe 1em Sly Sly Pro Lys Pro Pro Gin ArgVal Met Phe Thr Sim Asp 1em Lys 1em Pro Aia 5cr Phe Asp Ala Arg Glu Gin Trp
Human ACC TTC CTG GGT GGG CCC AAG CCA CCC CAG AGA GTT ATG TTT ACC GAG GAC CIG AAG CTG CCT GCA AGC TTC GAT GCA CGG GAA CAA TGG 270
Mouse ACT GIC CTG GGT GGA CCC AAA CTG CCA GGA AGG GTT GCG TTC GGT GAG GAC ATA GAT CTA CCT GAA ACC TIT GAT GCA CGG GAA CAA IGG
Rat G GA G A C A T G
Thr Val 1em Sly Sly Pro Lys 1em Pro Sly Arg Val Ala Phe Sly Sim Asp Ilie Asp Lem Pro Slu Thr Phe Asp Aia Arg Sly Sin Trp
Giv Sly 5cr Asn 5cr
100 120
Pro Sin Cys Pro Thr Ilie Lys Sly Ilie Arg Asp Sin Sly 5cr Cys Sly 5cr Cys Trp Ala Phe Sly Ala Val Sly Ala Ilie 5cr Asp Arg
Human CCA CAG TGT CCC ACC ATC AAA GAG ATC AGA GAC CAG GGC TCC TGT GGC TCC TGC TGG GCC TTC GGG GCT GIG GAA GCC AIC TCT GAC CGC 360
Mouse TCC AAC TGC CCG ACC All GGA CAG AlT AGA GAC CAG GGC ICC TGC GGC TCT TGT TGG GCA TTT GGG GCA GIG GAA GCC ATT TCT GAC CGA
Rat I C C C G T G
5cr Aso Cys Pro Thr Ilie Sly Sin Ile Arg Asp Sin Sly 5cr Cys Sly 5cr Cys Trp Ala Phe Sly Ala Val Sly Ala Ilie 5cr Asp Arg
Ala Met
t* ~~~~~~~~~~~~~140
Ilie Cys Ilie His Thr Aso Ala His Val 5cr Val Sly Val 5cr Ala Sly Asp 1em 1em Thr Cys Cys Sly 5cr Met Cys Sly Asp Sly Cys
Human ATC TGC ATC CAC ACC AAT GCG CAC GTC AGC GTG GAG GIG ICG GCG GAG GAC CTG CTC ACC IGC TGT GGC AGC ATG TGT GGG GAC GGC TGT 450
Mouse ACC TGC AlT CAC ACC AAT GGC CGA GTC AAC GTG GAG GIG ICT GCI GAA GAC CTG CIT ACT TGC TGI GGC ATC CAG TGI GGG GAC GGC TGT
Rat I I G C T T
Thr Cys Ilie His Thr Asn Sly Arg Val Asn Val Sly Val 5cr Ala Sly Asp 1ev 1ev Thr Cys Cys Sly Ilie Sin Cys Sly Asp Sly Cys
lie
160 180
Asm Sly Sly Tyr Pro Ala Sly Ala Trp Asn Phe Trp Thr Arg Lys Sly 1ev Val 5cr Sly Sly Lem Tyr Sly 5cr His Val Sly Cys Arg54
Human AAT GGI GSC TAT CCT GCI GAA GCT TGG AAC TIC TGG ACA AGA AAA GGC CTG GTI TCT GGI GGC CIC TAT GAA ICC CAT GTA GGG IGC AGA 54
Mouse AAT GGI GGC TAT CCC TCI GSA GCA TGG AAC TIC TGG ACA AAA AAA GGC CIG GTl TCA GGI GGA GIC TAC GAl TCI CAT AlA GGC IGC TTA
Rat TG I T A A A
Asm Sly Sly Tyr Pro 5cr Sly Ala Trp Asn Phe Trp Thr Lys Lys Sly Lem Val 5cr Sly Sly Val Tyr Asp 5cr His Ilie Sly Cys 1ev
Arg Asn
200
Pro Tyr 5cr Ilie Pro Pro Cys Sly His His Val Asn Sly 5cr Ar, Pro Pro Cys Thr Sly Sly Sly Asp Thr Pro Lys Cys 5cr Lys Ilie
Human CCS TAC ICC ATC CCI CCC 151 SAG CAC CAC SIC AAC GSC ICC CSG CCC CCA TSC ACS GGG GAS GSA SAT ACC CCC AAG TGT AGC AAG AIC 630
Mouse CCG TAC ACC AIC CCI CCC TSC GAG CAC CAT SIC AAT GSC ICC CGT CCC CCG TGT ACT GGG SAG GGG SAT ACT CCA ASS IGC AAC AAG AGC
Rat C I A T A C A A C A TG
Pro Tyr Thr Ilie Pro Pro Cys Sly His His Val Asn Sly 5cr Arg Pro Pro Cys Thr Sly Sly Sly Asp Thr Pro Arg Cys Asn Lys 5cr
Lys Met
220 240
Cys Sly Pro Sly Tyr 5cr Pro Thr Tyr Lys Sin Asp Lys His Tyr Sly Tyr Asn 5cr Tyr Ser Val 5cr Asn 5cr Sly Lys Asp Ilie Met
Human 1ST GAS CCT GSC TAC AGC CCG, ACC TAC AAA CAG SAC AAS CAC TAC GSA TAC AAT TCC TAC AGC SIC ICC AAT ASC SAG AAS SAC ATC ATG 720
Mouse TGT GAA SCT SGC TAC ICC CCA ICC TAC AAA GAS SAT AAG CAC III GGG TAC ACT ICC TAC AGC GIG TCI AAC AGT GIG AAG GAG AIC ATS
Rat S A S A A I S C A
Cys, Sly Ala Sly Tyr 5cr Pro 5cr Tyr Lys Sly Asp Lys His Phe Sly Tyr Thr 5cr Tyr 5cr Val 5cr Aso 5cr Val Lys Sim Ilie Met
Thr Tyr Asp Sly
260
Ala Sly Ilie Tyr Lys Asn Sly Pro Val Sly Sly Ala Phe 5cr Val Tyr 5cr Asp Phe Lcv 1ev Tyr Lys 5cr Sly Val Tyr Sin His Val
Human GCC GAG AIC TAC AAA AAC SGC CCC GTG GAG GSA SCT TIC ICT GTG TAT TCS SAC TIC CTG, CTC TAC AAG TCA GSA GIG TAC CAA CAC SIC 810
Mouse GCA GAA ATC TAC AAA AAT GGC CCA GIG SAG GGT GCC TIC ACT GIG TIT TCI SAC TIC ITS ACT TAC AAA ICA GSA GTA TAC AAG CAT GAA
Rat S I T C
Ala Sly Ilie Tyr Lys Asn Sly Pro Val Sly Sly Ala Phe Thr Val Phe 5cr Asp Phe Lev Thr Tyr Lys 5cr Sly Val Tyr Lys His Sly
280 300
Thr Sly Slm Met Met Sly Sly His Ala Ilie Arg Ilie 1ev Sly Trp Sly Val Siv Asm Sly Thr Pro Tyr Trp Lav Val Ala Asn 5cr Trp90
Human ACC GSA GAS ATG AIG SGI GGC CAT GCC ATC CGC AIC CIG GGC TGG GSA GIG GAG AAT GGC ACA CCC TAC TSS CIG, SIT GCC AAC ICC TGG 0
Mouse GCC GGT SAT ATS ATG GGI GGC CAC 6CC AIC CGC ATC CTG SIC IGG GSA GIA GAG AAI GSA SIT CCC TAC TGG CTG GCA GCC AAC TCI TGG
Rat S A I I S A A I A C
Ala Sly Asp Met Met Sly Sly His Ala Ilie Arg Ilie Lev Val Trp Sly Val Si. Asn Sly Val Pro Tyr Trp 1em Ala Ala Asm 5cr Trp
Val Sly Ilie Val
320
Aso Thr Asp Trp Sly Asp Asn Sly Phe Phe Lys Ilie 1em Arg Sly Sin Asp His Cys Sly Ilie Si. 5cr Sim Val Val Ala Sly Ilie Pro
Human AAC ACT SAC IGG GGT SAC AAI GGC TIC ITT AAA AlA CIC AGA GSA CAG, SAT CAC TGC GSA ATC GAA ICA GAA GIG GIG GCT GSA All CCA 990
Mouse AAC CII SAC TGG GGI SAT AAI GGC TIC ITT AAA AIC CTC AGA GSA GAA AAC CAC 151 GGC AlT GAA ICA GAA All GIG GCT GSA AIC CCA
Rat S I S A C
Asn 1ev Asp Trp Sly Asp Asn Sly Phe Phe Lys Ilie Lem Arg Sly Slu Asn His Cys Sly Ilie Sim 5cr Slm Ilie Val Ala Sly Ilie Pro
Val
t ~~~~~339
Arg Thr Asp Sin Tyr Trp Slm Lys Ilie
Human CSC ACC SAT CAG TAC TGG GAA AAG ATC IAAICTGCCGIGGGCCTGTCGTGCCAGICCIGSGGGCGAGAICGGGGSIAGAAAGICAIIIIAIICITTAAGTTCACGTAAGAT 1100
Mouse CGC ACT SAC CAG TAC IGG GSA AGA TIC IAATCTGCTTTGACTTCAIIGICCAGTCCTTAGGGGCTTITICCAAAATIIAGCGGCCIIGGCAGAGAATGAGGTAGACAGGG
Rat CSG GG S Al A AC AATGCA S S CT GSAIT
Arg Thr Asp Sin Tyr Trp Sly Arg Phe
Sin
Human AAGTCGCGGCGAGCGATGCAGCTCAGGCAGCTGTCTCACTTGTCGGAAAGCTTACACCCC1219
Mouse GGAICITSTATIC
Rat CIT GA CI
Human ACCGGGCTCCCGAATGGCTGATCTCGCACGTTGCCTCTACACACCAGACAAAAAGAGTAA1338
Human ACGGTCACGAGAGTCCACGTCCATCTCACATGTTCCTTTAAAACGGAAAGTTGGGCTTAG1457
Human 1576.--II ,-,.- I 111-1 1I 11 1I" 11 1 11,.I e-ATi TAATAf-AAt-TYATTT rT- a TAATrA
Human GT1GGGGAGCCAGTGGAACAGCGGGAGCCTGTGCTGGTTTGCAGATTGCCTCCTAATGACGCGGCTCAAAAGGAAACCAAGTGGTCAGGAGTTGTTTCTGACCCACTGATCTCTACTAC1695
Human CACAAGGAAAATAGT TTAGGAGAAACCAGCTTTTACTGTTTT TGAAAAATTACAGCTTCAC CCTGTCAAGTTAACAAGGAATGCCTGTGCCAATAAAAGGTTTCTCCAACTTG-po1 yA 1814
FIG. 3. Nucleotide and predicted amino acid sequences of human and mouse preprocathepsin B cDNAs. The composite human and mouse
sequences were constructed from sequenced DNA fragments from the overlapping clones as shown in Figs. 1 and 2. Nucleotides and predicted
amino acid residues in rat preprocathepsin B cDNA that differ from the mouse sequence are shown below it. The complete human 3' untranslated
region and a portion of the mouse and rat sequences are given. Arrows indicate potential cleavage sites for posttranslational processing.
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normal tissue preprocathepsin B mRNAs are transcribed
from the single cathepsin B gene.
The predicted primary structure ofhuman preprocathepsin
B contains 339 amino acids, including a 17-residue predom-
inantly hydrophobic sequence at the NH2 terminus. Such
signal sequences function to sequester the nascent protein
within the endoplasmic reticulum and are usually rapidly
removed after synthesis (22). We identified a potential
cleavage site at alanine-17 based on data from other known
prepeptide sequences, which indicate that cleavage often
occurs after the sequence Ala-X-Ala (23). Following the
prepeptide, the structure ofhuman procathepsin B consists of
a 62-residue NH2-terminal propeptide extension connected to
the 254-residue mature single chain form of mature cathepsin
B and is terminated by a 6-residue COOH-terminal peptide.
Mature cathepsin B has, also been isolated in a two-chain
form, and this form from human liver has been sequenced by
Ritonja et al. (21). In comparison, the cDNA-derived se-
quence predicts that the two-chain form is generated by
cleavage at two sites between residues 126 and 129, coupled
with the loss of a dipeptide. Otherwise, the two sequences are
in agreement except for an asparagine for aspartic acid
substitution at residue 228. The cleavage sites required to
generate mature cathepsin B from preprocathepsin B are
indicated by arrows in Fig. 3.
Outside the coding sequence, human preprocathepsin B
cDNA contains 791 nucleotides in the 3' untranslated region,
including a canonical hexanucleotide polyadenylylation sig-
nal, AATAAA (24), located 16 bp upstream from a stretch of
poly(dA). We also sequenced 191 bp in the 5' untranslated
region for a total of 1995 nucleotides (Fig. 3). Since an RNA
blot of human liver total RNA hybridized with labeled
preprocathepsin B cDNA revealed a single band of =-2300
nucleotides, we conclude that the 5' untranslated region
contains -400 nucleotides (data not shown).
The composite sequence of mouse preprocathepsin B
cDNA derived from clones XmCB24, XmCB54, and XmCB58
is also given in Fig. 3. Like human and rat preprocathepsin
B (for which we have now obtained the complete coding
sequence), the primary structure ofmouse preprocathepsin B
contains 339 residues. As noted earlier, the mouse and rat
sequences are strongly homologous, with 90.3% sequence
identity within the coding region. This conserved homology
extends into the 5' untranslated regions, which were com-
pared, and for =90 bp in the 3' untranslated region, as shown
in Fig. 3. Downstream from this segment, however, the two
sequences abruptly diverge and the mouse preprocathepsin B
cDNA contains a much longer 3' untranslated region, ex-
ceeding 1500 nucleotides. The evolutionary origin for the
extended 3' untranslated region in mouse is unknown, but it
may be due to mutational loss of a polyadenylylation signal
sequence or the insertion ofan additional exon in the genomic
sequence.
DISCUSSION
In this report, we present the complete coding sequences for
human and mouse preprocathepsin B from cDNA clones
isolated from human hepatoma and kidney phage libraries.
The mouse preprocathepsin B cDNA clones were obtained
from screening the hepatoma library after infiltration of this
tissue with host mouse reticuloendothelial cells (14). The
calculated molecular masses for human and mouse procath-
epsin B predicted from the coding sequences are 35.9 and
35.5 kDa, respectively, and with allowance for the addition of
carbohydrate moieties, these are close to the molecular
masses of the observed biosynthetic form in islets and to the
secreted form from tumor cells (9-11).
Together with the coding sequence for rat preprocathepsin
B, which we have recently completed (ref. 16; B.S.S., S.J.C.,
and D.F.S., unpublished data), the availability of the mouse
and human sequences provided an opportunity to compare
the cathepsin B structural gene from three mammalian
species and to search for conserved features that may be
functionally important. The nucleotide and amino acid se-
quence homologies between different regions of human,
mouse, and rat preprocathepsin B are summarized in Table
1. As shown, mature cathepsin B contained the highest
percentage of sequence identity followed by the NH2-
terminal proregion and the prepeptide. A direct comparison
of the primary structures in the latter two regions, however,
reveals that many of the amino acid substitutions are con-
servative (Fig. 4). Thus, changes in the prepeptide chain
retain its overall hydrophobic character. Similarly, in the
propeptide region the majority of the substitutions involve
residues with chemically analogous side chains.
One conserved residue in the propeptide that may be of
interest is the cysteine at position 59. It is possible that this
additional thiol amino acid plays a role in regulating the
enzymatic activity of procathepsin B by forming a disulfide
bond with the active-site cysteine-152, although the oxidation
state of the cysteines in either pro- or mature cathepsin B has
not yet been determined. Another conserved feature that may
be functionally important is that all three procathepsin B
sequences contain a potential second glycosylation site at
residue 38 with the identical recognition sequence Asn-Thr-
Thr. Mature cathepsin B contains a single glycosylation site
at asparagine-289. Glycosylation with mannose 6-phosphate
has been shown to be an important sorting signal for routing
proteins into lysosomes, but the mechanisms involved in this
process, including substrate specificity, have not been com-
pletely elucidated (25). In preliminary experiments, we have
found that rat procathepsin B contains a larger carbohydrate
moiety than that reported for the mature enzyme (26), and
this may be due in part to glycosylation at both sites (D.F.S.,
unpublished results).
A comparison of the primary structures of human, rat, and
mouse preprocathepsin B also provided clues on the possible
processing pathway for this enzyme. In particular, the
residue preceding the NH2-terminal leucine in mature
cathepsin B is different in all three sequences (Fig. 4). This
suggests that the initial cleavage in procathepsin B may occur
further upstream in the propeptide, followed by stepwise
removal ofthe NH2-terminal extension, possibly by an amino
dipeptidase activity. Within this context, it is noteworthy that
the second NH2-terminal residue in cathepsin B is a con-
served proline, which would not be a substrate for amino
Table 1. Homology between different regions of human,
rat, and mouse preprocathepsin B
Amino acid Nucleotide
(% homology) (% homology)
Prepeptide
Human/rat 8/17 (47%) 35/51 (69%)
Human/mouse 8/17 (47%) 33/51 (65%)
Rat/mouse 16/17 (94%) 49/51 (96%)
Proregion
Human/rat 42/62 (68%) 138/186 (74%)
Human/mouse 44/62 (71%) 137/186 (74%)
Rat/mouse 56/62 (90%) 173/186 (93%)
Cathepsin B
Human/rat 213/254 (84%) 629/762 (83%)
Human/mouse 210/254 (83%) 626/762 (82%)
Rat/mouse 237/254 (93%) 699/762 (92%)
COOH-terminal peptide
Human/rat 3/6 (50%) 14/18 (78%)
Human/mouse 3/6 (50%) 14/18 (78%)
Rat/mouse 6/6 (100%) 18/18 (100%)
Cathepsin B sequences compared are the single-chain forms.
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1 4 20
Human Met Trp Gin Leu Trp Ala Ser u Cys Cys Leu Leu Val Leu Ala Asn Arg Ser Arg Pro Ser Phe His Prol
Rat Met Trp Trp Ser Leu Ile Pro Leu Ser Cys Leu Leu Ala Leul Thr Ser Ala His Asp Lys Pro Ser Phe His Pro
Mouse Met Trp Trp Ser Leu Ile Leu LeJ Ser Cys Leu Le Ala Leu Thr Ser Ala His Asp Lys Pro Ser Phe His Pro
30 * 40 50
Human Val Ser Asp Glu Leu Val Asn Tyr Val Asn Lys ArgjAsn Thr Thr Trp Gin Ala Gly His Asn Phe Tyr Asn Val
Rat Leu Ser Asp Asp Met Ile Asn Tyr Ile Asn Lys Gin Asn Thr Thr Trp Gin Ala Gly Arg Asn Phe Tyr Asn Val
Mouse Leu Ser Asp Asp Leu Ile Asn Tyr Ile Asn LysJ 1n Asn Thr Thr Trp Gin Ala Gly Arg Asn Phe Tyr Asn Val
60 70
Human Asp Met Ser Tyr Leu Lys Arg Leu Cyso ly Thr Phe Leu Gly Gly Pro Lys Pro ro Gln jiigTVa- Met Phe Thr
Rat Asp Ile Ser Tyr Leu Lys Lys Pro Cys Gly Thr Val Leu Gly Gly Pro Lys Leu Pro Glu Arg Val GlyyPhe Ser
Mouse Asp Ile Ser Tyr Leu Lys Lys Leu Cys Gly Thr Val Leu Gly Gly Pro Lys Leu Pro Gly Arg ValAla Gly
+ 80
Human G6u Asp Leu Lys Leu Pro ...
Rat G6u Asp Ile Asn ILeu Pro ...
Mouse Glu Asp Ile Asp Leu Pro ..
FIG. 4. Homology between signal peptides and propeptide regions of human, rat, and mouse preprocathepsin B. Amino acid residues that
are identical in all three sequences are boxed; asterisk indicates potential glycosylation site; arrows indicate potential cleavage sites.
dipeptidase. Further processing steps include removal of the
COOH-terminal hexapeptide and cleavage at residues 126
and 129 (coupled with the loss of a dipeptide) to generate the
two-chain form. The latter cleavages probably occur within
the lysosome, since a mixture of single- and two-chain
cathepsin B has been isolated from this organelle and both
forms are enzymatically active (1).
In the foregoing scheme, the processing ofpreprocathepsin
B is postulated to be a multistep process during which
intermediates may be formed that possess biological activity.
The availability of the cDNA clones should facilitate the
identification and isolation of such intermediates. For exam-
ple, studies are in progress on the generation of antibodies to
synthetic peptides corresponding to different segments of
procathepsin B to be used to immunoprecipitate and char-
acterize biosynthetic intermediates. The cDNA clones will
also be used to test the function of specific residues via the
techniques of in vitro mutagenesis and subsequently assaying
the mutated genes for activity by transfection into cells. In
particular, it would be of interest to introduce substitutions
into cysteine-59 as well as the two potential glycosylation
sites.
We have used these preprocathepsin B cDNA clones as
hybridization probes to investigate the distribution of
cathepsin B mRNA in various tissues (27). In addition, these
cDNA clones can also be used to investigate the transcrip-
tional regulation of this gene in normal and tumor cells.
Although increased cathepsin B-like activity has been con-
sistently reported in metastatic tumors, the molecular iden-
tity of this activity has not been fully elucidated. A major
caveat in interpreting these studies is that the tumors are
often infiltrated with macrophages that contain substantial
amounts of cathepsin B (28). However, by using the
cathepsin B cDNA for hybridization in situ, it should be
possible to assay the expression of this gene directly in
individual cells (29).
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